-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
-
Summary
-
Cti Biopharma Corp quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2011 to Q4 2022.
- Cti Biopharma Corp Deferred Tax Assets, Gross for the quarter ending December 31, 2022 was $137M, a 46.7% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)